

FDA
U.S. FOOD & DRUG
ADMINISTRATION

Office of Pharmaceutical Quality Operations, Division II
4040 North Central Expressway, Suite 300
Dallas, TX 75204

www.fda.gov

Via UPS

Return Receipt Requested

07/11/2018

Hans Diehl

Managing Director

A & M Stabtest Gmbh

Kopernikusstr. 25

Bergheim, North Rhine-Westphalia, DE

Dear Managing Director, Hans Diehl:

The U.S. Food and Drug Administration (FDA) conducted an inspection at A & M Stabtest Gmbh, FEI:3003367682, located at Kopernikusstr. 25, Bergheim, 50126 DE from 04/26/2018 - 04/27/2018. FDA has determined that the inspection classification of this facility is "no action indicated" (NAI¹). Based on this inspection, this facility is considered to be in an acceptable state of compliance with regards to current good manufacturing practice (CGMP).

This letter is not intended as an endorsement or certification of the facility. It remains your responsibility to ensure continued compliance with CGMP.

An inspection classification of NAI for CGMP compliance will not directly negatively impact FDA's assessment of any pending marketing application referencing this facility. Please note, however, that application approval will depend on a product- and application-specific facility assessment conducted by CDER's Office of Pharmaceutical Quality. This letter does not address or reflect FDA's decision making with respect to any potential non-CGMP compliance issues.

FDA has concluded that this inspection is "closed" under 21 CFR 20.64(d)(3), and we are enclosing a copy of the narrative portion of the Establishment Inspection Report (EIR). It may reflect redactions made by FDA in accordance with the Freedom of Information Act (FOIA) and 21 CFR part 20. This, however, does not preclude you from requesting additional information under FOIA.

If you have any questions regarding this letter, you may contact Charles D Brown via telephone at 214-253-5245 or email at Charles.Brown@FDA.HHS.GOV.

Sincerely,

Charles D. Brown -S

Digitally signed by Charles D Brown -S
DN: cn=US, ou=US Government, email=HLS, ou=FDA,
cn=Charles D Brown -S
Date: 2018.07.11 08:41:55 -0500

Charles D Brown
SUPERVISORY CONSUMER SAFETY
OFFICER
PHARMACEUTICAL QUALITY
INVESTIGATION BRANCH

¹ See Inspection Classification Definitions, at <https://www.fda.gov/CECI/Inspections/ucm223231.htm>.